PlainPill

Tamoxifen

Also known as Nolvadex

The short answer. More people than not who report on Tamoxifen say it helped (64% of 75). It is most often used for hormones: 98% of 49 reports say that improved. It is well studied — 479 meta-analyses on PubMed. The most common complaint is fatigue.

What users report
64%helped75 reports · medium confidence
48 helped21 mixed6 didn't help

From 298 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
479
meta-analyses
1,597
RCTs
28,030
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Tamoxifen does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 479 meta-analyses on PubMed ↗ · 1,597 randomized trials ↗

Lancet · 2011 · Meta-analysis / systematic review
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Conclusion: 5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and death. ER status was the only recorded factor importantly predictive of the proportional reductions. Hence, the absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) without tamoxifen.

PubMed 21802721 ↗
Lancet · 2015 · Meta-analysis / systematic review
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Conclusion: Aromatase inhibitors reduce recurrence rates by about 30% (proportionately) compared with tamoxifen while treatments differ, but not thereafter. 5 years of an aromatase inhibitor reduces 10-year breast cancer mortality rates by about 15% compared with 5 years of tamoxifen, hence by about 40% (proportionately) compared with no endocrine treatment.

PubMed 26211827 ↗
Pharmacogenomics · 2024 · Meta-analysis / systematic review
Pharmacogenomics in Sri Lanka: a comprehensive systematic review of the research landscape and clinical implications

Conclusion: Additionally, nine studies developed, validated and tested novel assays for detecting key pharmacogenomically important variants.Conclusion: While pharmacogenomics research in Sri Lanka has made strides, more clinical studies and broader genomic research are needed. Overcoming challenges related to funding, public awareness and regional collaboration is essential to advance personalized medicine and improve therapeutic outcomes in Sri Lanka and South Asia.

PubMed 39540556 ↗
Registered clinical trials

684 human trials on ClinicalTrials.gov test Tamoxifen — 368 completed, 65 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer: Serious and life-threatening events associated with tamoxifen citrate in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary…”

Full label on DailyMed (NIH) ↗

FDA recalls

1 recall of products named for Tamoxifen. Most recent:

  • 2015-04-29 · Class II: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

5,727 adverse-event reports mention Tamoxifen. Most often reported:

  • Fatigue · 396
  • Nausea · 351
  • Diarrhoea · 278
  • Arthralgia · 276
  • Malignant neoplasm progression · 266
  • Pain · 247

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Tamoxifen B — a highly likely cause of liver injury (12–50 published cases). LiverTox entry ↗

US government research funding (NIH)

NIH has funded 105 research projects with Tamoxifen in the title, $80,239,010 in total (1985–2025). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Tamoxifen ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

fatigue ×3depression ×2low libido ×2headache ×2mood swings ×2joint pain ×1brain fog ×1prolactin increase ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“Dosage 5 mg starting at week 2. I upped the dose to 10 mg mid cycle due to slightly feeling suppressed.”
HelpedRead the discussion ↗
“Nolva for me has decently bad side effects so I might switch it up next time.”
MixedRead the discussion ↗
“I have never experienced a single side effect with Nolva and it has always worked.”
HelpedRead the discussion ↗
“This is now 2nd day on nolva and I swaer my balls are about back to normal. Energy is a bit better”
HelpedRead the discussion ↗
Read more Tamoxifen reviews →
Top discussions (5)

Tamoxifen compared

Other options for hormones

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate